It is unclear whether inhibition of PTPN22 or SHP1 alone can significantly improve anti-tumour CD8+ T-cell responses however in combination with ICB in murine models has demonstrated improved efficacy compared to monotherapy. This evidence concerns the gene CD8A and neoplasm.